Avacopan for the Treatment of ANCA-Associated Vasculitis

David R.W. Jayne,Petra Merkel,Thomas J. Schall,Pirow Bekker

Avacopan for the Treatment of ANCA-Associated Vasculitis

2021

David R.W. Jayne
Petra Merkel
Thomas J. Schall
Pirow Bekker

Abstract Background The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Methods In this randomized, controlle...

Keywords:

ANCA-Associated Vasculitis
Clinical trial
Gastroenterology
Anti-neutrophil cytoplasmic antibody
Equivalence Trial
C5a receptor
Medicine
Vasculitis
Internal medicine
Randomized controlled trial
Pharmacotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations